Edition:
United Kingdom

Kyowa Hakko Kirin Co Ltd (4151.T)

4151.T on Tokyo Stock Exchange

2,099JPY
1:04am GMT
Change (% chg)

¥23 (+1.11%)
Prev Close
¥2,076
Open
¥2,091
Day's High
¥2,112
Day's Low
¥2,090
Volume
231,700
Avg. Vol
1,179,236
52-wk High
¥2,227
52-wk Low
¥1,515

Latest Key Developments (Source: Significant Developments)

Reata Pharmaceuticals- Entered Third Supplement To Exclusive License & Supply Agreement With Kyowa Hakko
Thursday, 7 Dec 2017 

Dec 7 (Reuters) - Kyowa Hakko Kirin Co Ltd <4151.T>::REATA PHARMACEUTICALS-ON DEC 7 CO ENTERED THIRD SUPPLEMENT TO EXCLUSIVE LICENSE & SUPPLY AGREEMENT, BY & BETWEEN CO, KYOWA HAKKO KIRIN CO LTD (KHK).REATA SAYS THIRD SUPPLEMENT ALLOWS CO TO BEGIN PORTION OF PHASE 3 CLINICAL STUDY OF RTA 402 IN FIELD OF ALPORT SYNDROME IN JAPAN - SEC FILING.REATA PHARMACEUTICALS - ON DEC 7 CO ENTERED FOURTH SUPPLEMENT TO EXCLUSIVE LICENSE & SUPPLY AGREEMENT, BY & BETWEEN CO & KHK.  Full Article

Kyowa Hakko Kirin Announces FDA Acceptance For Filing And Priority Review Designation Of Mogamulizumab's Biologics License Application
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - Kyowa Hakko Kirin Co Ltd <4151.T>::KYOWA HAKKO KIRIN ANNOUNCES FDA ACCEPTANCE FOR FILING AND PRIORITY REVIEW DESIGNATION OF MOGAMULIZUMAB'S BIOLOGICS LICENSE APPLICATION.  Full Article

Kyowa Hakko Kirin says voluntary adoption of International Financial Reporting Standards (IFRS)
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Kyowa Hakko Kirin Co Ltd <4151.T>:Says it plans to adopt International Financial Reporting Standards (IFRS) as the new accounting method, to replace the Japanese Generally Accepted Accounting Principles .The change is to be implemented in its consolidated financial statements for the fiscal year ending December 31, 2017.  Full Article

ULTRAGENYX AND KYOWA HAKKO KIRIN ANNOUNCE FDA ACCEPTANCE OF BUROSUMAB’S BIOLOGICS LICENSE APPLICATION
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - Ultragenyx Pharmaceutical Inc ::ULTRAGENYX AND KYOWA HAKKO KIRIN ANNOUNCE FDA ACCEPTANCE AND PRIORITY REVIEW DESIGNATION OF BUROSUMAB’S BIOLOGICS LICENSE APPLICATION.ULTRAGENYX PHARMACEUTICAL INC - ‍PRESCRIPTION DRUG USER FEE ACT (PDUFA) ACTION DATE FOR BLA IS APRIL 17, 2018​.ULTRAGENYX PHARMACEUTICAL INC - FDA HAS NOT INFORMED COMPANIES WHETHER AN ADVISORY COMMITTEE MEETING TO DISCUSS APPLICATION WILL BE NEEDED​.ULTRAGENYX - FDA ACCEPTED BLA FOR BUROSUMAB TO TREAT PEDIATRIC, ADULT PATIENTS WITH X-LINKED HYPOPHOSPHATEMIA, GRANTED PRIORITY REVIEW STATUS​.  Full Article

R&I affirms Kyowa Hakko Kirin Co Ltd's rating at "A+" and announces stable outlook -R&I
Monday, 22 Aug 2016 

Kyowa Hakko Kirin Co Ltd <4151.T> : Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A+" -R&I .Rating outlook stable.  Full Article

Medgenics enters collaboration with Kyowa Hakko Kirin
Monday, 6 Jun 2016 

Medgenics Inc : Entered collaboration with Kyowa Hakko Kirin Co Ltd for development and commercialization of Kyowa Hakko's anti-light monoclonal antibody . Data from signal finding study in severe pediatric onset inflammatory bowel disease patients expected in first half 2017 . Upon completion of signal finding study in severe pediatric onset IBD, company will have option to license rights to develop program . Following exercise of option, medgenics will make a one-time, upfront payment in low single-digit millions to Kyowa Hakko Kirin .Co to have commercialization rights in U.S., Canada, will also add rights in europe if Kyowa Hakko Kirin selects licensing arrangement.  Full Article

BRIEF-Reata Pharmaceuticals- Entered Third Supplement To Exclusive License & Supply Agreement With Kyowa Hakko

* REATA PHARMACEUTICALS-ON DEC 7 CO ENTERED THIRD SUPPLEMENT TO EXCLUSIVE LICENSE & SUPPLY AGREEMENT, BY & BETWEEN CO, KYOWA HAKKO KIRIN CO LTD (KHK)